Protara's TARA-002 Shows 72% Complete Response Rate in BCG-Naïve Bladder Cancer Patients
核心洞察
Protara Therapeutics reported updated Phase 2 ADVANCED-2 trial data showing TARA-002 achieved a 72% complete response rate at any time in BCG-naïve non-muscle invasive bladder cancer patients.
The investigational cell therapy demonstrated durable responses with 69% complete response at six months and 50% at 12 months, while maintaining a favorable safety profile with no Grade 3 or greater treatment-related adverse events.
The FDA has provided written feedback supporting a registrational pathway for TARA-002 in BCG-naïve patients, with intravesical chemotherapy as an acceptable comparator rather than requiring BCG.
Protara Therapeutics announced promising updated interim results from its Phase 2 ADVANCED-2 trial of TARA-002, an investigational cell-based therapy for non-muscle invasive bladder cancer (NMIBC). The data, presented at the 26th Annual Meeting of the Society of Urologic Oncology, demonstrated a 72% complete response rate at any time in BCG-naïve patients with carcinoma in situ.
Strong Efficacy Signals in BCG-Naïve Population
The updated dataset included 31 BCG-naïve patients who received at least one dose of TARA-002, with 29 patients completing at least one response assessment and evaluable for efficacy as of the November 7, 2025 data cutoff. The therapy showed sustained activity with a 69% complete response rate at six months and 50% at 12 months.
"These encouraging TARA-002 results demonstrate meaningful and durable activity in BCG-naïve NMIBC patients," said Mark Tyson, M.D., MPH, Vice Chair for Research and Professor in the Department of Urology with the Mayo Clinic in Phoenix, Arizona, and ADVANCED-2 study investigator. "The clinically meaningful response rates at six and 12 months, coupled with a favorable safety and tolerability profile and simple administration that is even more streamlined than BCG, make TARA-002 a compelling potential treatment option in the BCG-naïve setting."
Among initial responders, 88% (14/16) maintained their response through six months and 100% (3/3) through 12 months. Re-induction therapy proved effective in salvaging initial non-responders, with 80% (4/5) of re-induced patients converting to a complete response at 6 months, and 100% (4/4) of those responders maintaining their complete response at 12 months.
Favorable Safety Profile
The treatment demonstrated a well-tolerated safety profile with no Grade 3 or greater treatment-related adverse events reported. The majority of treatment-related adverse events were Grade 1 and transient, with no patients discontinuing treatment due to adverse events. The most commonly occurring treatment-related adverse events were dysuria (13%), fatigue (13%), and hematuria (6%).
FDA Provides Regulatory Pathway Clarity
Protara received written feedback from the FDA supporting a registrational design for a controlled trial in BCG-naïve patients, including those who have never been exposed and those who have not received BCG within the last 24 months and are ineligible, contraindicated, cannot tolerate, do not have access to, or refuse BCG. Importantly, the FDA agreed that BCG is not required as a comparator and that intravesical chemotherapy is an acceptable comparator to TARA-002 in BCG-naïve patients.
The FDA has aligned with the primary endpoint of the trial as the complete response rate at month 6 with duration of response as a key secondary endpoint. The company continues to engage with the FDA to determine how to include BCG-exposed patients in its clinical trials, for whom no FDA-approved treatments are available.
Treatment Protocol and Mechanism
Patients in the ADVANCED-2 trial received an induction course of six weekly intravesical instillations of TARA-002, followed by a maintenance course of three weekly instillations every three months. Re-induction was permitted for eligible patients with residual carcinoma in situ and/or recurrent high-grade Ta disease.
TARA-002 is a first-in-class TLR2 (搜索)/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. The therapy's mechanism of action includes activation of innate and adaptive immune pathways within the bladder wall, producing a pro-inflammatory response with release of cytokines such as tumor necrosis factor-alpha, interferon-gamma, IL-6, IL-10, and IL-12. TARA-002 also directly kills tumor cells and triggers a host immune response by inducing immunogenic cell death.
Clinical Development Timeline
"These positive results continue to support TARA-002's potential in the NMIBC treatment landscape, and we look forward to finalizing a regulatory pathway for TARA-002 in BCG-naïve patients," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. The company remains on track to provide an update on the registrational BCG-unresponsive patient cohort in the ADVANCED-2 trial in the first quarter of 2026 and expects to complete enrollment of this cohort in the second half of 2026.
Market Context
Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing approximately 80% of bladder cancer diagnoses. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year, representing a significant patient population in need of effective treatment options.